IDH1 and glioblastoma: According to the World Health Organization (WHO) central nervous system (CNS) cancer classification, GBM can be divided into isocitrate dehydrogenase (IDH)-wild and IDH-mutant types, and IDH-wild type GBM has a relatively poorer prognosis (Yan et al., 2009; Louis et al., 2016).